60 Degrees Pharmaceuticals, Inc. Common Stock - Asset Resilience Ratio
60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) has an Asset Resilience Ratio of 23.12% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read SXTP current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2024–2025)
This chart shows how 60 Degrees Pharmaceuticals, Inc. Common Stock's Asset Resilience Ratio has changed over time. See SXTP net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down 60 Degrees Pharmaceuticals, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SXTP market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.24 Million | 23.12% |
| Total Liquid Assets | $1.24 Million | 23.12% |
Asset Resilience Insights
- Good Liquidity Position: 60 Degrees Pharmaceuticals, Inc. Common Stock maintains a healthy 23.12% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
60 Degrees Pharmaceuticals, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare 60 Degrees Pharmaceuticals, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for 60 Degrees Pharmaceuticals, Inc. Common Stock (2024–2025)
The table below shows the annual Asset Resilience Ratio data for 60 Degrees Pharmaceuticals, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 23.12% | $1.24 Million | $5.37 Million | -6.89pp |
| 2024-12-31 | 30.01% | $1.73 Million | $5.76 Million | -- |
About 60 Degrees Pharmaceuticals, Inc. Common Stock
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indicatio… Read more